15 May 2021 in Neurosurgical Review
31 August 2023 in Neuro-Oncology
JOJean-Pierre Kalala Okito
+2
Background: Survival data of diffuse adult-type glioma is mostly based on prospective clinical trials or small retrospective cohort studies. Real-world data with large patient cohorts is currently lacking. Methods: Using the nationwide, population-based Belgian Cancer Registry, all known histological reports of patients diagnosed with an adult-type diffuse glioma in Belgium between 2017 and 2019 were reviewed. The ICD-O-3 morphology codes were matched with the histological diagnosis. The gathered data were transformed into the 2021 World Health Organization classification of CNS tumors using the IDH- and 1p/19q-mutation status. Results: Between 2017 and 2019, 2233 diffuse adult-type gliomas were diagnosed in Belgium. Full molecular status was available in 67.1% of identified cases. The age-standardized incidence rate of diffuse adult-type glioma in Belgium was estimated at 8.55 per 100 000 person-years and 6.72 per 100 000 person-years for grade 4 lesions. Median overall survival time in IDH-wild-type glioblastoma was 9.3 months, significantly shorter compared to grade 4 IDH-mutant astrocytoma (median survival time: 25.9 months). The 3-year survival probability was 86.0% and 75.7% for grades 2 and 3 IDH-mutated astrocytoma. IDH-wild-type astrocytoma has a worse prognosis with a 3-year survival probability of 31.6% for grade 2 and 5.7% for grade 3 lesions. Conclusions: This registry-based study presents a large cohort of adult-type diffuse glioma with known molecular status and uses real-world survival data. It adds to the current literature which is mainly based on historical landmark trials and smaller retrospective cohort studies.
7 November 2019 in Journal of Neuro-Oncology
1 July 2017 in World Neurosurgery
1 December 2020 in Surgical Oncology
CBCaroline Van Den Broecke
+1
24 December 2025 in Brain and Spine
Temporal muscle thickness has been suggested as an independent prognostic marker for glioblastoma patient outcome. Various cohort studies show however conflicting results. This study therefore aims to reevaluate the prognostic value of different types of temporal muscle measurements in glioblastoma patients. A retrospective cohort study was performed including 137 patients diagnosed with IDH-wildtype glioblastoma. Temporal muscle thickness (TMT) and volume (TMV) were measured on preoperative MR-imaging. Next, these measurements were used in a multivariate Cox survival analysis to identify their possible prognostic value. These results were compared to the literature after systematic review of the Medline database. TMT has a moderate to strong linear correlation with total muscle volume (Pearson r = 0.6; P < 0.001). Glioblastoma patients “at risk for sarcopenia” show similar outcome compared to controls (median overall survival time: 13 months vs 11 months; P = 0.775). In a covariate Cox regression model, none of the temporal muscle measurements (TMT, TMV or sex-specific cut-off points) showed prognostic value for outcome in glioblastoma patients. Temporal muscle measurements show no independent relation to clinical outcome in IDH-wildtype glioblastoma patients. There seems adequate linear correlation of temporal muscle thickness and overall muscle volume. The literature on temporal muscle measurements lacks methodological consistency and should be interpreted with caution.